ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish <sup>177</sup>Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.

Related collections

Author and article information

Journal

Journal ID (publisher-id): NEN

Journal ID (nlm-ta): Neuroendocrinology

Journal ID (doi): 10.1159/issn.0028-3835

Title: Neuroendocrinology

Publisher: S. Karger AG

ISBN: 978-3-318-06158-1

ISBN: 978-3-318-06159-8

ISSN (Print): 0028-3835

ISSN (Electronic): 1423-0194

Publication date Subscription-year: 2017

Publication date (Print): September 2017

Publication date (Electronic): 13 April 2017

Volume: 105

Issue: 3

Pages: 295-309

Affiliations

^aCancer Imaging and Neuroendocrine Service, the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; ^bDepartment of Internal Medicine, Division of Nuclear Medicine, ENETS Centre of Excellence Rotterdam, Erasmus MC, and ^cCyclotron Rotterdam BV, Erasmus MC, Rotterdam, The Netherlands; ^dMemorial Sloan Kettering Cancer Center, New York, NY, USA; ^eNeuroendocrine Tumor Unit, Endocrinology and Metabolism Service, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; ^fMunich, Germany; ^gService de Gastroenterologie, Cliniques Universitaires St-Luc, Bruxelles, Belgium; ^hDepartment of Radiology, Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland; ⁱNeuroendocrine Tumour Unit, Royal Free Hospital, London, UK; ^jDepartment of Pathophysiology, Division of Endocrinology, National University of Athens, Athens, Greece; ^kGastroenterology and Endocrinology Center for Neuroendocrine Tumors Bad Berka, Bad Berka, Germany; ^lDepartment of Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden; ^mGastroenterology Department, Hampshire Hospitals NHS Trust, Hampshire, UK

Author notes

*Rodney J. Hicks, Cancer Imaging and Neuroendocrine Service, The Peter MacCallum Cancer Centre, 305 Grattan St, Melbourne, VIC 3000 (Australia), E-Mail Rod.Hicks@petermac.org

Author information

Rodney J. Hicks https://orcid.org/0000-0002-0758-0824

John Ramage https://orcid.org/0000-0003-4824-6600

Article

Publisher ID: 475526 Other ID: Neuroendocrinology 2017;105:295-309

DOI: 10.1159/000475526

PubMed ID: 28402980

SO-VID: 0124cd6a-45e9-4cb5-a854-9614f23643d0

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Date received : 12 December 2016

Date accepted : 06 April 2017

Page count

Tables: 4, References: 94, Pages: 15

Comments

Comment on this article

scite_

Cited by 87

See all cited by

- Version 1